Omeros Corporation OMER will release its fourth-quarter financial results after the closing bell on Monday, March 31.

Analysts expect the Seattle, Washington-based company to report quarterly loss at 78 cents per share, versus a year-ago loss of 69 cents per share, according to data from Benzinga Pro.

On March 21, Omeros issued an update of ongoing Zaltenibart Phase 3 PNH clinical trial program.

Omeros shares gained 4.7% to close at $8.92 on Thursday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.

• Needham analyst Serge Belanger reiterated a Hold rating on Jan. 17, 2025. This analyst has an accuracy rate of 68%.
• Cantor Fitzgerald analyst Olivia Brayer reiterated a Neutral rating on Nov. 14, 2024. This analyst has an accuracy rate of 62%.

Considering buying OMER stock? Here’s what analysts think:

Read This Next:

• Jim Cramer: Stryker Is A ‘Good’ Company, Says He Likes This Utilities Stock